GT Biopharma, Inc. (OXIS International, Inc.) - 10-K Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2008. The registrant, OXIS International, Inc. (referred to as GT Biopharma in the request metadata), is a smaller reporting company incorporated in Delaware. During 2008, the Company underwent a significant strategic pivot, exiting its primary revenue-generating businesses (research diagnostic assays and the BioCheck subsidiary) to focus on the development and marketing of neutraceutical products, specifically those containing L-Ergothioneine (ERGO). As of December 31, 2008, the Company had no employees, with operations conducted entirely by consultants.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Total Revenue | $1,143,000 | $1,724,000 |
| Net Income (Loss) | $(5,006,000) | $471,000 |
| Gross Profit | $234,000 | $996,000 |
| Gross Margin | 20% | 58% |
| Cash and Cash Equivalents (Year End) | $22,000 | $191,000 |
| Accumulated Deficit | $(74,854,000) | $(69,848,000) |
| Convertible Debentures (Liability) | $2,123,000 | $797,000 |
| Interest Expense | $1,657,000 | $1,014,000 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 34% ($581,000) primarily due to the loss of a significant manufacturing contract and lower product sales. License revenue dropped to zero from $500,000 in 2007.
- Net Loss: The Company swung from a net income of $471,000 in 2007 to a net loss of $5,006,000 in 2008. This was driven by a $2,978,000 loss on the disposition of a subsidiary (BioCheck) and increased interest expense.
- Asset Disposition: In June 2008, due to default on secured convertible debentures, the Company lost control of its majority-owned subsidiary, BioCheck, Inc., and OXIS Therapeutics, Inc., to debenture holders (Bristol Investment Fund, Ltd.) via a credit bid. In December 2008, the Company sold its remaining research assay assets to Percipio Biosciences, Inc. for a $250,000 promissory note.
- Liquidity Crisis: Cash holdings plummeted from $191,000 to $22,000. The Company reported a substantial doubt regarding its ability to continue as a going concern.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The auditors (Seligson & Gianattasio, LLP) issued a report with an explanatory paragraph noting substantial doubt about the Company's ability to continue as a going concern. The Company requires additional debt or equity financing to sustain operations.
- Debt Default: The Company defaulted on monthly redemption payments for its Secured Convertible Debentures starting in February 2007. As of December 31, 2008, the Company was 23 months behind on payments. This default led to the foreclosure and loss of major assets.
- Legal Proceedings:
- Steven Guillen: A judgment of $87,000 was entered against the Company in November 2008 regarding a separation agreement with a former CEO.
- Hines Vaf No Cal Properties: A lawsuit for breach of lease seeking approximately $60,000 in damages.
- AGI Dermatics: A dispute regarding patent assignment and licensing was in mediation/arbitration stages.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, citing a lack of segregation of duties and risks of executive override due to a very small staff.
- Future Strategy: The Company plans to focus on selling neutraceuticals based on L-Ergothioneine (ERGO) but has no assurance of success in generating sufficient revenue or obtaining financing.
Investor Verification Checklist
- Capital Adequacy: Verify if the Company has secured the additional financing required to survive 2009, given the $22,000 cash balance and substantial operating losses.
- Debt Obligations: Confirm the status of the $2,123,000 convertible debenture liability and the $2,688,000 deficiency judgment from the BioCheck foreclosure.
- Asset Realization: Assess the collectability of the $250,000 promissory note received from Percipio Biosciences for the sale of assay assets.
- Legal Exposure: Monitor the resolution of the $87,000 judgment against former CEO Steven Guillen and the lease dispute with Hines Vaf No Cal Properties.
- Going Concern Status: Review subsequent filings to determine if the "substantial doubt" regarding the Company's ability to continue operations has been resolved.